About SHINE Technologies, LLC Headquartered in Janesville, Wisconsin, SHINE is an industry leader in next-generation fusion, developing innovative fusion-based technology that combines safety, ...

Lantheus Holdings, Inc. ("Lantheus" or the "Company") (NASDAQ: LNTH), the leading radiopharmaceutical-focused company dedicated to helping clinicians ...

Capstan Medical, a developer of robotic-enabled, minimally invasive solutions to address heart valve disease, today announced the appointment of Marshall Mohr to its Board of Directors to further ...

Century Health Care Consultants, a leading provider of consulting, licensing, accreditation, and training services for home care agencies nationwide, today announced a strategic alliance with Homecare ...

US and EU regulatory designations provide critical development resources to advance novel tumor detection technology Curadel Pharma, a pioneer in zwitterionicity and innovator in advanced radiotherapi ...

To lead the integration and growth of the SPECT business, SHINE has named Michael Rossi as CEO of SHINE SPECT USA, LLC.

Radiation therapy has been a foundation of cancer care for more than a century. From early X-ray machines to today’s ...

Radiopharmaceuticals have rapidly evolved from a specialised therapeutic niche into a cornerstone of modern oncology. By combining molecular targeting with controlled radiation delivery, they add a ...

Radiopharmaceuticals are one of the most exciting frontiers in oncology and targeted therapies today. By combining biologically active molecules with radionuclides, radiopharmaceuticals can deliver ...

After seeing some of its financial momentum slow this year, Bicycle Therapeutics has received a push from two U.K. nuclear agencies, securing up to 400 tons of reprocessed uranium the biotech needs to ...

A new database targeting chronic urinary tract infections (UTIs)—a long-overlooked condition that may begin in childhood—is set to help researchers uncover why millions of women and girls worldwide ...

Execution of a 15-year contract, including an option to renew with UK Nuclear Decommissioning Authority (Cumbria, UK) for access to up to 400 tonnes of reprocessed uranium (RepU), with the potential ...